**Prescribing information and adverse event reporting information for EYLEA® (aflibercept) can be accessed here or via the QR code located on the last page of this document.**

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

## STREAMLINE YOUR CLINIC WITH EYLEA® (aflibercept) 8 mg

# EYLEA 8 mg DOSING REGIMENS IN nAMD AND DMO

EYLEA 8 mg is licensed up to 6 months intervals,* allowing you to extend stable patients out to as few as 2 injections per year.[1–5]

***Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q24 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.[1]**

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).[1]

**For UK healthcare professionals only.**

DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. Q16, every 16 weeks. Q24, every 24 weeks. SmPC, Summary of Product Characteristics. T&E, treat and extend. VEGF, vascular endothelial growth factor.

**References**
**1.** EYLEA® 114.3 mg/mL Summary of Product Characteristics. **2.** Lanzetta P, *et al.* Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, Phase 3 trial. Lancet. 2024;403(10432):1141-1152. **3.** Brown DM, *et al.* Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, Phase 2/3 trial. Lancet. 2024;403(10432):1153-1163. **4.** Lanzetta P. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation. **5.** Wykoff CC. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.

PP-EYL_8mg-GB-0614 | August 2025

# TREAT YOUR ELIGIBLE PATIENTS WITH FLEXIBILITY

## Extend up to 6-month intervals* and experience flexibility with optional reloading for patients switching from other anti-VEGF agents†[1]

**For patients initiating treatment, EYLEA 8 mg can be used as part of a T&E regimen to lengthen intervals‡**

Tx-naïve | Switch

**Treatment-naïve patients:**




**Allowing you to extend stable patients out to as few as 2 injections per year†‡[1]**

The frequency of monitoring visits should be based on the patient's status and at the physician's discretion.[1]

**Dosing diagram for illustrative purposes only.**

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to 6 months (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable.[1]
†Stable patients switching to EYLEA 8 mg do not require loading doses and can maintain or extend previous treatment intervals after the first injection of EYLEA. Consult the SmPC for full posology.[1]
‡For patients who have previously been treated with EYLEA 2 mg or other anti-VEGF medicinal products and are switching to EYLEA 8 mg, the treatment regimen can differ from that used for treatment-naïve patients. Treatment intervals should be determined based on visual and/or anatomic outcomes: in patients with stable visual and anatomic outcomes, previous treatment intervals can be maintained or extended after the first injection of EYLEA 114.3 mg/mL, such as with a T&E dosing regimen; in patients with suboptimal visual and/or anatomic outcomes, treatment with EYLEA 8 mg may begin with 1 injection per month for up to 3 consecutive doses followed by adjustment of injection intervals, such as with a T&E dosing regimen.[1]

Q16, every 16 weeks; Q24, every 24 weeks; SmPC, Summary of Product Characteristics; T&E, treat and extend; Tx, treatment; VEGF, vascular endothelial growth factor.

**Reference: 1.** EYLEA® 114.3 mg/mL Summary of Product Characteristics.

# TREAT YOUR ELIGIBLE PATIENTS WITH FLEXIBILITY

## Extend up to 6-month intervals* and experience flexibility with optional reloading for patients switching from other anti-VEGF agents†[1]

**Patients who have previously been treated with EYLEA 2 mg or other anti-VEGF medicinal products can maintain or extend their current interval when switching to EYLEA 8 mg, with or without reloading‡**

Tx-naïve | Switch




The frequency of monitoring visits should be based on the patient's status and at the physician's discretion.[1]

**Dosing diagram for illustrative purposes only.**

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to 6 months (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable.[1]
†Stable patients switching to EYLEA 8 mg do not require loading doses and can maintain or extend previous treatment intervals after the first injection of EYLEA. Consult the SmPC for full posology.[1]
‡For patients who have previously been treated with EYLEA 2 mg or other anti-VEGF medicinal products and are switching to EYLEA 8 mg, the treatment regimen can differ from that used for treatment-naïve patients. Treatment intervals should be determined based on visual and/or anatomic outcomes: in patients with stable visual and anatomic outcomes, previous treatment intervals can be maintained or extended after the first injection of EYLEA 114.3 mg/mL, such as with a T&E dosing regimen; in patients with suboptimal visual and/or anatomic outcomes, treatment with EYLEA 8 mg may begin with 1 injection per month for up to 3 consecutive doses followed by adjustment of injection intervals, such as with a T&E dosing regimen.[1]

Q16, every 16 weeks; Q24, every 24 weeks; SmPC, Summary of Product Characteristics; T&E, treat and extend; Tx, treatment; VEGF, vascular endothelial growth factor.

**Reference: 1.** EYLEA® 114.3 mg/mL Summary of Product Characteristics.

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.

Either click **here** or scan the QR code for prescribing information and adverse event reporting information.

For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.